HAYWARD, Calif., Nov. 21, 2024 /PRNewswire/ — Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, the company’s first gene therapy drug for the…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.